FDA authorised restart of the COVID-19 AZD1222 vaccine US phase III trial
On Oct. 23, 2020, AstraZeneca announced that the clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, had…
Johnson & Johnson prepared to resume phase 3 ENSEMBLE trial of COVID-19 vaccine candidate in the US
On Oct. 23, 2020, Johnson & Johnson announced that it was preparing to resume recruitment in the pivotal…
FDA approved first treatment for COVID-19
On Oct. 22, 2020, the FDA approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric…
Landmark study 31/A5349 on the treatment of drug-susceptible TB
On Oct. 22, 2020, the World Health Organizationﾒs Global TB Programme welcomed the results from a landmark study…
Roche announced collaboration with Atea Pharmaceuticals to develop potential oral treatment for COVID-19 patients
On Oct. 22, 2020, Roche and Atea Pharmaceuticals announced they had joined forces in the fight against COVID-19…
Oxford Immunotec selected as sole supplier of UK T cell testing for SARS-CoV-2 COVID vaccine trials
On Oct. 22, 2020, Oxford Immunotec announced that it had been selected to provide T cell testing to…
Scientists used gene therapy and a novel light-sensing protein to restore vision in mice
On Oct. 22, 2020, a newly developed light-sensing protein called the MCO1 opsin restored vision in blind mice…
WHO and Wikimedia Foundation expanded access to trusted information about COVID-19 on Wikipedia
On Oct. 22, 2020, the World Health Organization (WHO) and the Wikimedia Foundation announced a collaboration to expand…
IAVI, Merck, and Serum Institute joined forces to develop monoclonal antibodies for COVID-19
On Oct. 22, 2020, IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges,…
Amyris and the Infectious Disease Research Institute entered into exclusive license for novel RNA vaccine platform
On Oct. 22, 2020, Amyris and the Infectious Disease Research Institute (IDRI) announced the signing of a Collaboration…
Vacaville unveiled California Biomanufacturing Center and next generation of biotech development
On Oct. 22, 2020, the City of Vacaville announced the start of the next generation of development of…
Moderna completed enrollment of phase 3 COVE study of mRNA vaccine against COVID-19
On Oct. 22, 2020, Moderna announced that it had completed enrollment of 30,000 participants for the Phase 3…
Todos Medical announced distribution agreement with Adial Pharma to market Assure/FaStep Covid-19 antibody tests
On Oct. 22, 2020, Todos Medical announced that it had entered into an exclusive supply agreement with U.S….
Biotechnology | COVID-19 | FDA | Therapeutics
FDA approved Gilead’s antiviral Veklury (remdesivir) for treatment of COVID-19
On Oct. 22, 2020, Gilead Sciences announced that the FDA had approved the antiviral drug Veklury (remdesivir) for…
Landmark TB trial identified shorter-course treatment regimen
On Oct. 21, 2020, results from an international, randomized, controlled clinical trial indicated that a four-month daily treatment…
ViiV Healthcare analysis showed no antiretroviral therapy interruptions due to COVID-19
On Oct. 21, 2020, ViiV Healthcare, majority owned by GSK, with Pfizer and Shionogi Limited as shareholders, announced…
ImmunityBio, NantKwest announced first patient dosed in phase 1 clinical trial of second-generation COVID-19 vaccine candidate
On Oct. 21, 2020, ImmunityBio and NantKwest announced that the first patient had been dosed in the Phase…
Purdue Pharma reached agreement with U.S. Department of Justice
On Oct. 21, 2020, Purdue Pharma announced that it had entered into an agreement with the U.S. Department…
CerTest Biotec and BD announced CE Mark for combination COVID-19, Influenza, RSV test
On Oct. 21, 2020, CerTest Biotec, along with BD (Becton, Dickinson), announced that the VIASURE SARS-CoV-2 (N1 +…
Merck announced positive topline results from phase 3 adult studies evaluating V114 15-valent pneumococcal conjugate vaccine
On Oct. 20, 2020, Merck announced findings from two additional Phase 3 studies evaluating the safety, tolerability and…
Final report confirmed remdesivir benefits for COVID-19
On Oct. 20, 2020, the NIH announced that the researchers had completed the Adaptive COVID-19 Treatment Trial (ACTT-1),…
PerkinElmer immunoassay identiied therapeutic compounds capable of disrupting the SARS-CoV-2 spike protein/ACE2 interaction
On Oct. 20, 2020, PerkinElmer announced that a research team at the National Center for Advancing Translational Sciences…
Agriculture | Artificial Intelligence | Biotechnology | CMO | CRO | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
U.S. Department of Defense approved $87 million for newest bioindustrial manufacturing innovation institute
On Oct. 20, 2020, the U.S. Department of Defense announced an $87 million, seven-year award to the BioIndustrial…
BioMedomics’ COVID-19 IgM/IgG Rapid Test approved by INVIMA in Colombia
On Oct. 20, 2020, BioMedomics announced that the National Institute for Food and Drug Surveillance (INVIMA) had provided…
OPKO Health’s BioReference Laboratories launched multiplex COVID-19 and influenza A/B test
On Oct. 20, 2020, BioReference Laboratories, an OPKO Health company, announced that it was accepting specimens for a…
European Investment Bank provided Immunic with ﾀ245 million to support development of COVID-19 therapy
On Oct. 20, 2020, the European Investment Bank (EIB) and Immunic announced the signing of a ﾀ24.5 million…
Evidence review confirmed CDC guidance about infectivity of novel coronavirus
On Oct. 20, 2020, researchers at Oregon Health & Science University (OHSU) and Oregon State University (OSU) reported…
Alberta Enterprise Corporation invested additional $5 million to benefit Alberta startups
On Oct. 19, 2020, Alberta Enterprise announced that it had invested an additional $5 million into its third…
Study discovered gene that helps us know when itﾒs time to urinate
On Oct. 19, 2020, researchers annoounced they had discovered that a gene, called PIEZO2, may be responsible for…
Mateon’s phase 2 global study for OT-101/ TGF- Inhibitor against COVID-19 cleared for patient enrollment in Argentina
On Oct. 19, 2020, Mateon Therapeutics announced the receipt of approval from Republica Argentina Poder Ejecutivo Nacional, the…